1. Adrenergic receptors are divided into alpha and beta families, each with multiple subtypes. Which of the following correctly identifies the primary G protein coupling and a key physiological effect for each of the four major adrenergic receptor subtypes?

• A) Alpha-1 receptors couple to Gs (the stimulatory G protein that activates adenylyl cyclase) and produce smooth muscle relaxation — beta-1 receptors couple to Gq (a G protein that activates phospholipase C) and produce cardiac stimulation — alpha-2 receptors couple to Gi (the inhibitory G protein that reduces cAMP) and produce inhibition of norepinephrine release — beta-2 receptors couple to Gs and produce bronchodilation.
• B) Alpha-1 receptors couple to Gq/11 (a G protein that activates phospholipase C, generating IP3 and DAG as second messengers) producing smooth muscle contraction in blood vessels, iris, and sphincters — alpha-2 receptors couple to Gi (the inhibitory G protein) reducing cAMP and inhibiting norepinephrine release from presynaptic terminals — beta-1 receptors couple to Gs (the stimulatory G protein) increasing cAMP and PKA activity, producing increased heart rate, conduction velocity, and contractility — beta-2 receptors couple to Gs, increasing cAMP in bronchial smooth muscle and producing bronchodilation.
• C) Alpha-1 and alpha-2 receptors both couple to Gs — the distinction between them is purely anatomical: alpha-1 receptors are postsynaptic and alpha-2 receptors are presynaptic; beta-1 and beta-2 receptors both couple to Gq and produce the same signal transduction cascade regardless of tissue.
• D) All four adrenergic receptor subtypes couple to Gq but activate different phospholipase isoforms — alpha-1 activates phospholipase C-beta, alpha-2 activates phospholipase A2, beta-1 activates phospholipase D, and beta-2 activates phospholipase C-gamma; the different phospholipase isoforms produce organ-specific responses despite the shared Gq coupling.
• E) Beta-1 receptors couple to Gi and produce negative chronotropy — beta-2 receptors couple to Gs and produce bronchodilation — alpha-1 receptors couple to Gq and produce vasoconstriction — alpha-2 receptors couple to Gs and produce central sympathetic activation.

2. Muscarinic receptors are divided into five subtypes (M1 through M5). Which of the following correctly identifies the primary locations and signal transduction mechanisms of M1, M2, and M3 — the three subtypes most relevant to clinical pharmacology?

• A) M1 receptors are located at the SA node (the heart's natural pacemaker) and AV node (the electrical relay between atria and ventricles) — activation produces bradycardia through Gi-mediated reduction of cAMP; M2 receptors are located in glands (salivary, lacrimal, and sweat glands) — activation produces secretion through Gq and IP3 mechanisms; M3 receptors are located in autonomic ganglia — activation produces slow excitatory postsynaptic potentials (EPSPs — small electrical signals that partially depolarize the postsynaptic neuron).
• B) M2 receptors are the only muscarinic subtype in the peripheral autonomic nervous system — M1 and M3 exist only in the CNS; atropine's peripheral effects (tachycardia, mydriasis, dry mouth, and urinary retention) are therefore all mediated through M2 receptor blockade at peripheral effector organs.
• C) M3 receptors are located exclusively in the eye — activation contracts the iris sphincter pupillae (producing miosis — pupil constriction) and ciliary muscle (producing accommodation — lens focusing for near vision); all other peripheral muscarinic effects are mediated by M1 receptors at smooth muscle and M2 receptors at glands.
• D) M1 receptors are located in CNS neurons and autonomic ganglia — activation through Gq/11 produces slow excitatory EPSPs contributing to ganglionic signal integration and cognitive function; M2 receptors are located at the SA node, AV node, and atrial muscle — activation through Gi produces bradycardia, slowed AV conduction, and reduced atrial contractility; M3 receptors are located on smooth muscle and glands throughout the body — activation through Gq/11 produces smooth muscle contraction (bronchi, GI tract, bladder detrusor, and iris sphincter) and glandular secretion (salivary, lacrimal, and sweat glands).
• E) M1, M2, and M3 receptors are all located on cardiac muscle and produce identical physiological effects — the distinction between them is pharmacokinetic, with M1 having the highest affinity for acetylcholine and M3 the lowest; this affinity gradient determines which subtype is activated first at low ACh concentrations.

3. A patient with symptomatic bradycardia (abnormally slow heart rate) is given atropine 1 mg IV and his heart rate increases from 38 to 88 bpm within 2 minutes. Which receptor subtype does atropine block at the SA node, and what is the signal transduction mechanism that normally produces vagal bradycardia?

• A) Atropine blocks M2 muscarinic receptors at the SA node — vagal acetylcholine activates M2 receptors, which couple to Gi (the inhibitory G protein); Gi activation has two parallel effects: first, the alpha subunit of Gi inhibits adenylyl cyclase (the enzyme that produces cAMP), reducing cAMP and slowing the pacemaker current (If — an inward current that drives the spontaneous depolarization of SA node cells between beats); second, the beta-gamma subunits of Gi directly open IKACh channels (potassium channels that are specifically activated by acetylcholine through G protein coupling), allowing potassium to flow out of the cell and hyperpolarizing the membrane — making it harder for the SA node to fire; atropine blocks M2 and removes both inhibitory signals, allowing the intrinsic pacemaker rate to recover.
• B) Atropine blocks M1 muscarinic receptors at the SA node — vagal acetylcholine activates M1 receptors, which couple to Gq, generating IP3 (inositol trisphosphate) that causes calcium release from the sarcoplasmic reticulum (the intracellular calcium store); the calcium rise activates a calcium-dependent kinase that phosphorylates and inhibits L-type calcium channels (the voltage-gated calcium channels that contribute to SA node depolarization), slowing pacemaker activity.
• C) Atropine blocks M3 muscarinic receptors at the SA node — vagal acetylcholine activates M3 receptors, which couple to Gs (the stimulatory G protein) and paradoxically increase cAMP; the elevated cAMP activates a phosphodiesterase (an enzyme that breaks down cAMP) faster than cAMP is produced, creating a net decrease in cAMP that slows pacemaker activity.
• D) Atropine blocks M2 muscarinic receptors, but the mechanism of bradycardia is direct physical channel blockade rather than G protein signaling — acetylcholine inserts into the ion channel pore of M2 itself, physically blocking sodium and calcium entry without any G protein intermediary; atropine displaces acetylcholine from the channel pore, restoring ion conductance.
• E) Atropine blocks beta-1 adrenergic receptors at the SA node — the bradycardia reflects insufficient sympathetic beta-1 stimulation rather than excessive vagal tone; atropine's beta-1 blocking property paradoxically increases heart rate by preventing inhibitory catecholamine effects on the SA node.

4. Beta-2 adrenergic receptors mediate bronchodilation in airway smooth muscle. A patient with acute severe asthma is given nebulized salbutamol (albuterol), a selective beta-2 agonist. Which of the following correctly traces the signal transduction pathway from beta-2 receptor activation to airway smooth muscle relaxation?

• A) Salbutamol binds beta-2 receptors on bronchial smooth muscle — these receptors couple to Gi (the inhibitory G protein), which inhibits adenylyl cyclase and reduces cAMP; reduced cAMP reduces PKA activity, which reduces phosphorylation of phospholamban (a protein in the sarcoplasmic reticulum membrane), increasing SERCA pump activity (the pump that moves calcium from the cytoplasm back into the sarcoplasmic reticulum) and removing calcium from the cytoplasm — producing smooth muscle relaxation.
• B) Salbutamol binds beta-2 receptors on bronchial smooth muscle — these receptors couple to Gq, activating phospholipase C (an enzyme that generates IP3 and DAG from membrane phospholipids); IP3 releases calcium from the endoplasmic reticulum; the calcium rise activates MLCP (myosin light chain phosphatase) rather than MLCK (myosin light chain kinase — the enzyme that drives smooth muscle contraction), dephosphorylating myosin light chains and producing smooth muscle relaxation.
• C) Salbutamol binds beta-2 receptors on bronchial epithelial cells — beta-2 activation increases ciliary beat frequency and mucus clearance, reducing airway obstruction from mucus plugging; improvement in airflow results from mucociliary clearance rather than smooth muscle relaxation.
• D) Salbutamol binds beta-2 receptors on mast cells (immune cells in the bronchial mucosa) — beta-2 activation on mast cells inhibits IgE-mediated degranulation (the release of inflammatory mediators stored in mast cell granules), preventing histamine and leukotriene release; bronchodilation results not from direct smooth muscle relaxation but from reduced inflammatory mediator release.
• E) Salbutamol binds beta-2 receptors on bronchial smooth muscle — these receptors couple to Gs (the stimulatory G protein), which activates adenylyl cyclase (the enzyme that converts ATP into cAMP); the resulting rise in cAMP activates PKA (protein kinase A — an enzyme that phosphorylates target proteins to change their activity); PKA phosphorylates and inactivates MLCK (myosin light chain kinase — the enzyme that normally triggers smooth muscle contraction by phosphorylating myosin); with MLCK inactivated, myosin light chains are dephosphorylated by the constitutively active MLCP (myosin light chain phosphatase), and the actin-myosin cross-bridges that maintain smooth muscle tone dissolve — producing relaxation and bronchodilation within seconds to minutes.

5. Alpha-1 adrenergic receptor activation produces vasoconstriction in blood vessel smooth muscle. Which of the following correctly identifies the signal transduction steps from alpha-1 activation to increased vascular tone?

• A) Alpha-1 receptor activation → Gs coupling → adenylyl cyclase activation → cAMP increase → PKA activation → phosphorylation of MLCK → increased MLCK activity → myosin light chain phosphorylation → smooth muscle contraction and vasoconstriction.
• B) Alpha-1 receptor activation → Gi coupling → adenylyl cyclase inhibition → cAMP decrease → PKA inhibition → reduced phosphorylation of MLCP → increased MLCP activity → myosin light chain dephosphorylation → smooth muscle relaxation and vasodilation.
• C) Alpha-1 receptor activation → Gq/11 coupling → phospholipase C-beta activation → PIP2 hydrolysis → IP3 and DAG generation → IP3 triggers calcium release from the endoplasmic reticulum → calcium binds calmodulin (a calcium-sensing protein that acts as a molecular switch) → the calcium-calmodulin complex activates MLCK → MLCK phosphorylates myosin light chains → actin-myosin cross-bridge formation → smooth muscle contraction and vasoconstriction; DAG simultaneously activates PKC (protein kinase C), which sensitizes the contractile apparatus to calcium and activates Rho kinase, further sustaining vasoconstriction.
• D) Alpha-1 receptor activation → G12/13 coupling → RhoGEF activation → Rho-GTP → ROCK (Rho-associated kinase) activation → MLCP phosphorylation and inactivation → this is the only pathway by which alpha-1 receptors produce vasoconstriction; Gq coupling is irrelevant to the vascular contractile response.
• E) Alpha-1 receptor activation → Gs coupling → adenylyl cyclase activation → cAMP increase → cAMP directly opens L-type calcium channels (voltage-gated calcium channels in the plasma membrane) without any protein kinase intermediary → calcium influx → calmodulin activation → MLCK activation → smooth muscle contraction.

6. Presynaptic alpha-2 adrenergic autoreceptors (receptors on the same nerve terminal that released the neurotransmitter, detecting that neurotransmitter as a feedback signal) regulate norepinephrine release by providing negative feedback. Which of the following correctly describes the signal transduction mechanism of alpha-2 activation and the pharmacological consequence of blocking these autoreceptors?

• A) Alpha-2 receptor activation couples to Gs, increasing cAMP and PKA activity — PKA phosphorylates voltage-gated calcium channels, increasing calcium entry and amplifying norepinephrine release; alpha-2 blockers therefore reduce norepinephrine release by preventing this cAMP-mediated calcium channel activation.
• B) Alpha-2 autoreceptor activation reduces norepinephrine synthesis (not release) by coupling to Gi and reducing cAMP-dependent phosphorylation of tyrosine hydroxylase (TH — the rate-limiting enzyme in norepinephrine synthesis); reduced TH activity slows norepinephrine production, but the effect on norepinephrine release is indirect and occurs only after hours of autoreceptor activation.
• C) Alpha-2 autoreceptor activation reduces norepinephrine release by directly binding norepinephrine molecules in the synaptic cleft and sequestering them before they can diffuse to postsynaptic adrenergic receptors — the autoreceptor functions as a molecular sponge rather than through any signal transduction cascade.
• D) Alpha-2 receptor activation on the presynaptic terminal couples to Gi (the inhibitory G protein), reducing cAMP and reducing PKA activity — additionally, the beta-gamma subunits of Gi directly inhibit voltage-gated N-type calcium channels (the calcium channels that trigger norepinephrine exocytosis — the calcium-dependent process of vesicle fusion and neurotransmitter release) on the presynaptic terminal, reducing calcium entry during action potentials and thereby reducing the amount of norepinephrine released per nerve impulse; blocking alpha-2 autoreceptors with drugs such as yohimbine or idazoxan removes this inhibitory brake, increasing norepinephrine release per action potential and potentiating sympathetic effects — yohimbine has been studied in orthostatic hypotension (abnormally low blood pressure on standing) because of this norepinephrine-releasing property.
• E) Alpha-2 receptor activation couples to Gq, activating phospholipase C and generating IP3 — the resulting calcium release from the endoplasmic reticulum activates calmodulin-dependent protein kinase II (CaMKII — a kinase activated by calcium-calmodulin), which phosphorylates and inactivates the vesicle fusion machinery responsible for norepinephrine exocytosis; alpha-2 blockers remove this CaMKII-mediated inhibition, increasing norepinephrine release.

7. Muscarinic M2 and M3 receptors are both activated by acetylcholine and both are present in cardiac tissue, yet they produce different effects. Which of the following correctly explains how two muscarinic receptor subtypes in the same organ can produce different physiological outcomes?

• A) M2 receptors couple to Gi (the inhibitory G protein) and are located on SA node and AV node pacemaker and conduction cells — their activation reduces heart rate and slows AV conduction, reflecting the dominant parasympathetic action on cardiac automaticity; M3 receptors couple to Gq/11 and are located on coronary vascular endothelial cells (the cells lining the inside of coronary arteries) rather than on cardiomyocytes directly — their activation triggers endothelial production of nitric oxide (NO — a short-lived signaling gas that diffuses from endothelium into adjacent vascular smooth muscle), producing coronary vasodilation; the two receptor subtypes produce different outcomes because they couple to different G proteins, activate different second messenger systems, and are expressed in different cell types within cardiac tissue — not because of any difference in acetylcholine affinity.
• B) M2 and M3 receptors in the heart have identical signal transduction mechanisms but are expressed in different cellular compartments — M2 is expressed in the nucleus and M3 is expressed at the plasma membrane; the nuclear M2 receptor reduces gene transcription for the pacemaker protein HCN4 (the protein that forms the funny current If channel), while plasma membrane M3 increases HCN4 gene transcription; the opposing transcriptional effects produce opposing changes in pacemaker current density and heart rate over days to weeks.
• C) M2 and M3 receptors both couple to Gi in the heart, but M3 is present at much lower density than M2 — at physiological acetylcholine concentrations M2 dominates and reduces heart rate; at supraphysiological acetylcholine concentrations reached during extreme vagal activation, M3 becomes occupied and its Gi coupling produces a paradoxical cAMP increase through a signaling crosstalk mechanism.
• D) M2 and M3 receptors have opposing effects in the heart because they couple to opposing G proteins — M2 couples to Gi (producing bradycardia through cAMP reduction) while M3 couples to Gq (producing effects through calcium signaling); the fact that two receptor subtypes for the same neurotransmitter can couple to different G proteins and produce different second messengers explains why the tissue distribution of receptor subtypes determines the physiological outcome of muscarinic stimulation, not just the presence of acetylcholine.
• E) M2 and M3 receptors produce different effects because they are located on opposing cell types in the same tissue — M2 receptors on cardiomyocytes (heart muscle cells) produce bradycardia through Gi; M3 receptors on cardiac fibroblasts (structural support cells) produce tachycardia through Gq-mediated release of prostaglandin I2 (prostacyclin), which activates IP receptors on the SA node to increase pacemaker rate.

8. Nicotinic receptors (ligand-gated ion channels — receptors that open a pore directly when the neurotransmitter binds, without any G protein intermediary) exist at both autonomic ganglia (NN receptors) and the neuromuscular junction (NM receptors). Which of the following correctly identifies a pharmacologically important difference between NN and NM receptor subtypes?

• A) NN and NM receptors are pharmacologically identical — both are pentameric (five-subunit) sodium channels with the same subunit composition; the apparent clinical selectivity of ganglionic blockers and neuromuscular blockers reflects pharmacokinetic rather than pharmacodynamic differences, as each drug distributes preferentially to the tissue where it exerts its effect.
• B) NN receptors are GPCRs (G protein-coupled receptors — receptors that signal through G proteins rather than by directly opening ion channels) while NM receptors are ligand-gated ion channels; ganglionic blockers therefore work by blocking G protein coupling while neuromuscular blockers work by blocking the ion channel pore.
• C) NM receptors are homomeric (composed of five identical subunits) while NN receptors are heteromeric (composed of different subunit types) — the homomeric structure of NM receptors makes them calcium-impermeable, whereas the heteromeric NN receptors are sodium-selective; this ion selectivity difference, rather than any binding site geometry difference, explains why neuromuscular blocking drugs are selective for NM over NN receptors.
• D) NN and NM receptors differ only in their anatomical location — the subunit composition, ion selectivity, and pharmacological sensitivity to blocking drugs are identical; the clinical selectivity of neuromuscular blockers for the neuromuscular junction over autonomic ganglia reflects the 10,000-fold higher receptor density at the neuromuscular junction rather than any molecular pharmacological difference.
• E) NN receptors are composed predominantly of alpha3 and beta4 subunits (the protein building blocks that assemble to form the receptor-channel complex) while NM receptors at the adult neuromuscular junction are composed of alpha1 (two copies), beta1, delta, and epsilon subunits — this different subunit composition creates different binding site geometries and explains why neuromuscular blocking drugs (rocuronium, vecuronium, and succinylcholine) are selective for NM receptors and produce muscle paralysis without ganglionic blockade, while ganglionic blockers (hexamethonium, trimethaphan) are selective for NN receptors and block autonomic transmission without causing neuromuscular blockade at clinical doses.

9. A patient with glaucoma (elevated intraocular pressure caused by impaired drainage of aqueous humor from the anterior chamber of the eye) is prescribed pilocarpine eye drops. Pilocarpine is a direct muscarinic agonist. Which of the following correctly identifies both the receptor subtype activated and the mechanism by which pilocarpine reduces intraocular pressure?

• A) Pilocarpine activates M3 muscarinic receptors on the ciliary muscle (a ring of smooth muscle inside the eye that controls both lens shape for focusing and the trabecular meshwork drainage angle) — M3 activation through Gq/11 produces contraction of the ciliary muscle; ciliary muscle contraction pulls open the trabecular meshwork (the drainage network through which aqueous humor normally exits the eye into Schlemm's canal), reducing resistance to aqueous humor outflow and lowering intraocular pressure; simultaneously, M3 activation on the iris sphincter pupillae produces miosis (pupil constriction), which is a predictable on-target side effect rather than a separate mechanism.
• B) Pilocarpine activates M2 muscarinic receptors on the trabecular meshwork endothelial cells — M2 activation through Gi reduces intracellular cAMP in these cells, reducing active secretion of aqueous humor into the anterior chamber; the reduction in aqueous humor production (rather than improved drainage) is the primary mechanism of intraocular pressure reduction.
• C) Pilocarpine activates M1 muscarinic receptors on the ciliary body epithelium (the cells that secrete aqueous humor) — M1 activation through Gq reduces the activity of carbonic anhydrase (an enzyme that provides bicarbonate for aqueous humor secretion), reducing aqueous humor production; this secretion-reducing mechanism is identical to that of carbonic anhydrase inhibitors such as acetazolamide.
• D) Pilocarpine activates beta-2 adrenergic receptors on the ciliary body — this adrenergic activation increases cAMP and stimulates aqueous humor secretion initially, but through a receptor desensitization mechanism (loss of response with repeated activation) paradoxically reduces secretion after 30–60 minutes; the net pressure-lowering effect reflects this delayed desensitization phase.
• E) Pilocarpine activates M3 muscarinic receptors on the corneal endothelium (the single cell layer lining the inside of the cornea) — M3 activation increases corneal endothelial pump activity, drawing fluid from the anterior chamber into the corneal stroma (the thick middle layer of the cornea) and reducing the volume of aqueous humor available to generate intraocular pressure.

10. A patient is given a non-selective beta-adrenergic blocker (propranolol) for hypertension. Three days later he develops wheezing and his peak flow (a measure of how fast air can be expelled from the lungs, used to assess airway obstruction) drops from his baseline of 480 L/min to 230 L/min. Which adrenergic receptor subtype does propranolol block in the airway, and why does this produce bronchoconstriction?

• A) Propranolol blocks beta-1 receptors in the airway, removing sympathetic bronchodilatory tone — beta-1 receptors are the dominant adrenergic subtype in bronchial smooth muscle, and their blockade removes the Gs-cAMP-PKA-mediated relaxation signal, allowing the resting vagal M3-mediated bronchomotor tone to act unopposed.
• B) Propranolol blocks alpha-2 receptors in the airway, removing presynaptic inhibition of norepinephrine release — the resulting increase in synaptic norepinephrine paradoxically produces bronchoconstriction through activation of unblocked alpha-1 receptors on bronchial smooth muscle.
• C) Propranolol blocks beta-2 adrenergic receptors in bronchial smooth muscle — beta-2 blockade removes the Gs-cAMP-PKA-mediated bronchodilatory signal that normally counterbalances resting vagal M3 muscarinic bronchoconstrictor tone; in a patient with pre-existing bronchial hyperresponsiveness (exaggerated sensitivity of the airways to constrictor stimuli, as seen in asthma and COPD), removing this sympathetic bronchodilatory counterbalance allows unopposed M3-mediated bronchoconstriction, producing clinically significant airway obstruction; this is why non-selective beta-blockers are absolutely contraindicated in asthma and require extreme caution in COPD.
• D) Propranolol blocks beta-2 receptors on mast cells in the bronchial mucosa — beta-2 blockade disinhibits IgE-mediated mast cell degranulation (the release of inflammatory contents stored inside mast cells), causing histamine and leukotriene release; bronchoconstriction is therefore inflammatory and mast cell-mediated rather than resulting from any direct effect on bronchial smooth muscle receptor subtypes.
• E) Propranolol blocks beta-3 adrenergic receptors in the airway — beta-3 receptors mediate bronchodilation in humans through a cAMP-independent mechanism involving activation of nitric oxide synthase; propranolol's beta-3 blockade removes this NO-mediated bronchodilatory signal and allows airway smooth muscle to contract under the influence of resting M3 cholinergic tone.

11. Phenylephrine is a selective alpha-1 adrenergic agonist used as a nasal decongestant and as a vasopressor (a drug that raises blood pressure by constricting blood vessels) in anesthetic practice. Which of the following correctly predicts the expected heart rate response to IV phenylephrine and explains the mechanism?

• A) IV phenylephrine produces direct tachycardia (abnormally fast heart rate) by activating beta-1 adrenergic receptors on the SA node — phenylephrine has modest beta-1 agonist activity at high IV doses that outweighs its alpha-1 selectivity, producing simultaneous vasoconstriction and direct cardiac stimulation.
• B) IV phenylephrine produces no change in heart rate because alpha-1 receptors are not expressed in the heart — phenylephrine's purely vascular alpha-1 mechanism does not engage any cardiac receptor subtypes, and the baroreceptor reflex is not triggered by alpha-1-mediated vasoconstriction.
• C) IV phenylephrine produces direct bradycardia by activating alpha-1 receptors on the SA node — alpha-1 receptor activation in the SA node couples to Gq and raises intracellular calcium, which activates calcium-dependent potassium channels and hyperpolarizes the pacemaker cell membrane, slowing the firing rate.
• D) IV phenylephrine produces reflex bradycardia — phenylephrine's alpha-1-mediated vasoconstriction raises mean arterial pressure; baroreceptors (stretch receptors in the aortic arch and carotid sinus that detect blood pressure changes) detect the pressure rise and send signals to the nucleus tractus solitarius (NTS — a brainstem nucleus that receives baroreceptor input and coordinates the reflex autonomic response); the NTS increases vagal (parasympathetic) outflow to the SA node, activating M2 receptors and slowing heart rate; this reflex bradycardia is a predictable physiological consequence of any vasopressor that raises blood pressure without directly stimulating the heart.
• E) IV phenylephrine produces reflex tachycardia by activating alpha-1 receptors on baroreceptor nerve endings in the aortic arch, sensitizing them to detect lower blood pressure — the sensitized baroreceptors report falsely low pressure to the NTS, which responds by reducing vagal tone and increasing sympathetic drive to the SA node, accelerating heart rate despite the actual rise in blood pressure.

12. A 72-year-old woman is prescribed oxybutynin (a non-selective muscarinic antagonist — a drug that blocks all muscarinic receptor subtypes) for overactive bladder. She develops confusion, impaired memory, constipation, dry mouth, and urinary hesitancy. Which of the following correctly maps each side effect to the specific muscarinic receptor subtype responsible?

• A) All four side effects are caused by M2 blockade — M2 receptors mediate all peripheral muscarinic effects including GI motility, salivary secretion, detrusor contraction, and cognitive function; M1 and M3 receptors do not contribute to any of these peripheral effects and are only relevant to cardiac and vascular pharmacology respectively.
• B) Confusion and memory impairment → M1 blockade in CNS neurons (M1 receptors contribute to cognitive function and cholinergic neurotransmission in the hippocampus and cortex; their blockade produces anticholinergic cognitive impairment, particularly in elderly patients whose cognitive reserve — the brain's capacity to compensate for neurological impairment — is reduced); constipation → M3 blockade in GI smooth muscle (M3 activation normally drives peristaltic contractions; blockade slows GI motility throughout the gut); dry mouth → M3 blockade at salivary gland acinar cells (M3 activation drives salivary secretion; blockade reduces it, producing xerostomia — dry mouth); urinary hesitancy → M3 blockade at the bladder detrusor (M3 on the detrusor drives contraction for voiding; excessive blockade impairs voiding despite the therapeutic intent of reducing involuntary contractions).
• C) Confusion → M3 blockade in the CNS; constipation → M1 blockade in myenteric ganglia (the nerve network within the gut wall); dry mouth → M2 blockade at salivary glands; urinary hesitancy → M1 blockade at the detrusor; the different receptor subtypes mediating each side effect explain why selective M3 antagonists should theoretically produce no CNS, GI, or salivary side effects.
• D) All four side effects reflect M1 blockade — M1 receptors mediate all cholinergic function in both CNS and peripheral tissues; M2 and M3 receptors exist only as pharmacological reserve subtypes that compensate for M1 blockade during high cholinergic demand states such as vagal stimulation or cholinergic drug administration.
• E) Confusion and memory impairment → M2 blockade in hippocampal neurons; constipation → M2 blockade at myenteric ganglia; dry mouth → M1 blockade at parotid gland acinar cells; urinary hesitancy → M2 blockade at the detrusor; this subtype pattern explains why selective M2 antagonists should theoretically spare salivary secretion while still reducing GI motility and improving bladder control.

13. Clonidine is a centrally acting antihypertensive that reduces blood pressure by acting as an agonist at alpha-2 adrenergic receptors (and imidazoline I1 receptors — a separate class of receptors in the brainstem that also reduce sympathetic outflow) in the brainstem. Which of the following correctly explains why clonidine produces a broader autonomic footprint (a wider set of effects across multiple organ systems) than a peripheral alpha-1 blocker such as prazosin?

• A) Clonidine produces broader effects than prazosin because clonidine is a larger molecule with higher lipophilicity (fat solubility) that distributes to more tissues and engages a greater number of receptor subtypes through non-specific binding; prazosin's narrower effect reflects its small molecular size and restricted tissue distribution rather than any pharmacodynamic receptor selectivity.
• B) Clonidine produces broader effects than prazosin because clonidine blocks both alpha-1 and alpha-2 receptors simultaneously — the dual alpha blockade affects both postsynaptic vascular tone (alpha-1) and presynaptic norepinephrine release (alpha-2), producing compounding reductions in sympathetic activity; prazosin blocks only alpha-1 and therefore produces only a single layer of sympatholysis.
• C) Clonidine and prazosin produce identical autonomic footprints — both reduce blood pressure by reducing peripheral vascular resistance through alpha receptor blockade; the distinction between centrally acting and peripherally acting is a pharmacokinetic classification reflecting CNS penetration, not a pharmacodynamic distinction producing different organ-level effects.
• D) Clonidine produces broader effects than prazosin because clonidine activates beta-2 adrenergic receptors in addition to alpha-2 receptors — the beta-2 component produces cardiac slowing through a paradoxical inhibitory effect on SA node automaticity, while the alpha-2 component produces vasoconstriction that partially offsets the vasodilatory effects; the combination of beta-2-mediated bradycardia and alpha-2-mediated vasoconstriction produces the broader cardiovascular profile.
• E) Clonidine acts at alpha-2 receptors and imidazoline I1 receptors in the nucleus tractus solitarius (NTS — a brainstem nucleus that receives and integrates cardiovascular sensory signals) and the rostral ventrolateral medulla (RVLM — the brainstem's primary sympathetic command center that drives tonic sympathetic preganglionic outflow); by reducing the RVLM's excitatory output to all sympathetic preganglionic neurons simultaneously, clonidine reduces sympathetic tone globally — lowering blood pressure, reducing heart rate, and producing sedation (through alpha-2 activation in the locus coeruleus — a brainstem nucleus that regulates arousal and wakefulness) and dry mouth (through reduced sympathetic salivary gland tone); prazosin blocks only peripheral alpha-1 receptors on vascular smooth muscle, producing vasodilation without affecting heart rate or CNS function — its effect is anatomically restricted to vascular alpha-1 receptors.

14. Beta-3 adrenergic receptors couple to Gs and are expressed primarily in adipose tissue (fat cells), the bladder detrusor muscle (the main muscle of the bladder that contracts during urination), and the heart. Which of the following correctly identifies a drug that selectively activates beta-3 receptors and explains its therapeutic application?

• A) Isoproterenol is a selective beta-3 agonist used for refractory bradycardia — beta-3 activation in the SA node couples to Gs and increases cAMP, accelerating the funny current (If — the inward current that drives SA node pacemaker depolarization) and raising heart rate; isoproterenol is preferred over atropine for bradycardia because its beta-3 selectivity avoids the dry mouth and urinary retention produced by non-selective muscarinic antagonists.
• B) Salmeterol is a selective beta-3 agonist used for long-term asthma control — beta-3 activation in bronchial smooth muscle couples to Gs, increases cAMP, activates PKA, inactivates MLCK, and produces sustained bronchodilation lasting 12 hours; beta-3 selectivity avoids the cardiovascular effects of non-selective beta agonists while maintaining full bronchodilatory efficacy.
• C) Mirabegron is a selective beta-3 adrenergic agonist used for overactive bladder — beta-3 receptor activation in bladder detrusor smooth muscle couples to Gs, increases cAMP, activates PKA, inactivates MLCK (myosin light chain kinase — the enzyme that drives smooth muscle contraction), and produces detrusor relaxation during the bladder filling phase; relaxing the detrusor during filling increases bladder capacity and reduces the involuntary detrusor contractions that produce urgency and urge incontinence; because mirabegron acts through beta-3 rather than blocking muscarinic receptors, it avoids the M1-mediated cognitive impairment, M3-mediated dry mouth, and M3-mediated constipation produced by non-selective muscarinic antagonists such as oxybutynin.
• D) Dobutamine is a selective beta-3 agonist used for acute heart failure — beta-3 activation in ventricular myocytes (heart muscle cells) couples to Gs and increases cAMP, increasing the force of cardiac contraction (positive inotropy); dobutamine's beta-3 selectivity avoids the peripheral vasodilation and tachycardia associated with beta-1 and beta-2 agonists, making it ideal for cardiogenic shock.
• E) Terbutaline is a selective beta-3 agonist used as a tocolytic (a drug that stops preterm labor) — beta-3 activation in uterine smooth muscle couples to Gs, increases cAMP, and relaxes the myometrium (uterine muscle); terbutaline's beta-3 selectivity avoids the tachycardia and hypokalemia associated with beta-2 agonists used for the same indication.

15. Having worked through the complete adrenergic and muscarinic receptor subtype map in this module, which of the following most accurately captures the clinical significance of receptor subtype diversity for drug development and prescribing?

• A) Receptor subtype diversity is primarily important for basic scientists — clinicians only need to know the therapeutic effects of drugs, not the specific receptor subtypes responsible; adverse effects are managed empirically by monitoring and dose adjustment rather than by predicting them from receptor binding profiles.
• B) Receptor subtype diversity explains why drugs acting on the same neurotransmitter system can have radically different therapeutic applications and side effect profiles — a selective M3 antagonist (targeting smooth muscle and glands) can treat overactive bladder with fewer cognitive side effects than a non-selective muscarinic antagonist that also blocks M1 receptors in the CNS; a selective beta-1 blocker can reduce heart rate in heart failure with less risk of bronchoconstriction than a non-selective beta blocker that also blocks beta-2 receptors in the airway; a selective beta-3 agonist can relax the bladder without producing tachycardia from beta-1 activation; in each case the therapeutic advantage is achieved by targeting the specific subtype expressed in the desired tissue while sparing subtypes expressed in tissues that would produce adverse effects — receptor subtype selectivity is therefore an engineered pharmacological property with direct clinical consequences.
• C) Receptor subtype diversity is a pharmacokinetic phenomenon — different receptor subtypes exist because drugs distribute to different tissues and encounter different pH environments, which alter the drug's binding affinity; the subtype differences observed pharmacologically reflect different chemical microenvironments rather than genuinely different protein structures.
• D) Receptor subtype diversity creates clinical problems without corresponding benefits — because no drug achieves absolute receptor subtype selectivity, all drugs that target one subtype inevitably produce equivalent effects at all related subtypes; the concept of subtype selectivity is a marketing construct rather than a pharmacological reality with measurable clinical impact.
• E) Receptor subtype diversity is important only for understanding adverse effects, not for understanding therapeutic effects — therapeutic effects always involve the most abundant receptor subtype in the target tissue, while adverse effects arise from off-target binding to minority subtypes; drug development therefore focuses on eliminating minority subtype binding while preserving binding to the majority subtype in each target tissue.